Roivant Sciences (ROIV) EBT Margin (2020 - 2025)
Roivant Sciences (ROIV) posted EBT Margin of 12520.47% for Q4 2025, down 23.67% on a QoQ basis from 10123.74% in Q3 2025, and down 1029296.0% year-over-year from N/an in Q4 2024.
Roivant Sciences (ROIV) EBT Margin (2020 - 2025) Analysis & Trends
Roivant Sciences' EBT Margin history runs 6 years deep, the most recent figure standing at 12520.47% for Q4 2025.
- Quarterly EBT Margin fell 1029296.0% year-over-year to 12520.47% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 5249.7% (down 1293691.0% YoY) and the FY2026 annual result came in at 3203.12%, down 85710.0% from the prior year.
- EBT Margin was 12520.47% for Q4 2025 at Roivant Sciences, down from 10123.74% in the prior quarter.
- Across five years, EBT Margin topped out at 21751.34% in Q4 2023 and bottomed at 12520.47% in Q4 2025.
- A 5-year average of 3125.93% and a median of 2503.44% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin soared 2483540 bps — and 2024, when it sank 2397885 bps.
- Roivant Sciences' EBT Margin stood at 1372.62% in 2021, then slumped by 125 bps to 3084.05% in 2022, then soared by 805 bps to 21751.34% in 2023, then tumbled by 110 bps to 2227.51% in 2024, then sank by 462 bps to 12520.47% in 2025.
- Business Quant data shows ROIV's EBT Margin at 12520.47% in Q4 2025, 10123.74% in Q3 2025, and 12408.39% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12,520.47% |
| Sep 30, 2025 | -10,123.74% |
| Jun 30, 2025 | -12,408.39% |
| Dec 31, 2024 | -2,227.51% |
| Sep 30, 2024 | -5,014.15% |
| Jun 30, 2024 | -245.81% |
| Dec 31, 2023 | 21,751.34% |
| Sep 30, 2023 | -6,617.49% |
| Jun 30, 2023 | -1,508.01% |
| Dec 31, 2022 | -3,084.05% |
| Sep 30, 2022 | -2,503.44% |
| Jun 30, 2022 | -8,098.75% |
| Dec 31, 2021 | -1,372.62% |
| Sep 30, 2021 | -1,610.35% |
| Jun 30, 2021 | -1,305.56% |
| Dec 31, 2020 | -4,796.89% |
| Sep 30, 2020 | -3,989.95% |
| Jun 30, 2020 | -428.68% |